tldrdailynews.com logo

Novo Nordisk's CagriSema Shows Promising Weight Loss Results with Mild Side Effects

1 min read
Source: STAT
Novo Nordisk's CagriSema Shows Promising Weight Loss Results with Mild Side Effects
Photo: STAT
TL;DR

Novo Nordisk's obesity drug CagriSema shows similar safety and efficacy to Eli Lilly's Zepbound, with initial weight loss of around 20% over 68 weeks, but the rate of weight loss plateaus, raising questions about its long-term effectiveness.

Topics:top-newshealth#cagrisema#clinical-trials#health#novo-nordisk#obesity#weight-loss
Share this article
  1. Novo Nordisk’s amylin obesity drug keeps performing like Zepbound  STAT
  2. Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects  Reuters
  3. Novo hunts for ‘maximum potential’ from obesity drug CagriSema  Financial Times
  4. Novo Nordisk Obesity Shot Tied to Greater Weight Loss at Lower Doses  Bloomberg.com
  5. CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM  Yahoo Finance

Want the full story? Read the original reporting

Read on STAT